Switching From or To Jardiance (Empagliflozin): SGLT2 Inhibitor Swap Protocols

How empagliflozin works, and why that matters for switching

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the proximal renal tubule, which normally reabsorbs most of the glucose filtered by the kidney 1. Blocking that transporter lets excess glucose pass into the urine instead of returning to the bloodstream, producing a mild osmotic diuresis and a modest caloric loss. Dapagliflozin, canagliflozin, and ertugliflozin all act on the same transporter through the same mechanism, so a within-class switch does not introduce a new pharmacologic pathway.

The agents differ in pharmacokinetics, not in what they do. Empagliflozin's prescribing information describes a relatively short elimination half-life, generally cited as roughly half a day. Dapagliflozin and canagliflozin are described in their own labeling as having similarly short, roughly half-day half-lives; this article does not cite their exact figures because their prescribing information was not part of the source material reviewed here, and those numbers should be confirmed against each drug's current label before being quoted to a patient. The practical point is the same regardless of the exact hours: stopping one SGLT2 inhibitor and starting another the next day leaves no clinically meaningful gap in coverage.

This is different from switching between drug classes entirely. Moving from a DPP-4 inhibitor to an SGLT2 inhibitor activates a different glucose-lowering pathway and may call for closer monitoring during the transition, discussed further below.

Dose mapping between empagliflozin and other SGLT2 inhibitors

FDA-approved doses are not numbered consistently across this drug class, which can confuse patients and prescribers moving between products. Based on comparative glycemic-efficacy data reported across trials of these agents, a reasonable approximate mapping is:

• Empagliflozin 10 mg (the usual starting dose) is roughly comparable to dapagliflozin 10 mg and canagliflozin 100 mg.
• Empagliflozin 25 mg (the higher approved dose for type 2 diabetes) is roughly comparable to canagliflozin 300 mg. Dapagliflozin has no higher glycemic dose; 10 mg is its ceiling for type 2 diabetes.

These are approximate equivalences drawn from pooled trial comparisons, not a precise conversion formula, and a prescriber may reasonably choose a different starting dose based on renal function, blood pressure, or hypoglycemia risk from concurrent insulin or sulfonylurea use.

For heart failure, empagliflozin and dapagliflozin are each approved at a single dose (10 mg), so a switch between them for a heart failure indication is generally a 1:1 change with no uptitration needed 4. For chronic kidney disease, EMPA-KIDNEY used empagliflozin 10 mg 5, DAPA-CKD used dapagliflozin 10 mg 6, and CREDENCE tested canagliflozin at 100 mg 7, again, switches between these doses for a kidney-protection indication are generally 1:1.

Why clinicians switch SGLT2 inhibitors

Formulary and prior-authorization pressure is a commonly cited driver of within-class SGLT2 inhibitor switches in claims-based research; the exact proportion of switches attributable to formulary reasons varies by dataset and time period, so a single precise percentage should be treated cautiously rather than quoted as a fixed rate. The 2024 ADA Standards of Care support substitution within a drug class when a specific medication is unavailable to or not tolerated by a patient 9.

Side-effect history is a second reason. The CANVAS program identified a higher rate of lower-limb amputation with canagliflozin than placebo (6.3 versus 3.4 per 1,000 patient-years) 10, a signal that led to an FDA boxed warning that was later removed after further data review. Some clinicians still preferentially avoid or switch away from canagliflozin in patients with peripheral arterial disease or prior amputation, even though the current label no longer carries that warning.

A third reason is trial evidence specific to a patient's condition. EMPA-REG OUTCOME showed a 38% relative reduction in cardiovascular death with empagliflozin versus placebo (3.7% versus 5.9%; HR 0.62, 95% CI 0.49-0.77) in people with type 2 diabetes and established cardiovascular disease 1. For a patient on a different SGLT2 inhibitor who develops atherosclerotic disease, some prescribers weigh this dataset when deciding whether to switch to empagliflozin, though no head-to-head trial has directly compared cardiovascular outcomes between SGLT2 inhibitors. Heart failure guidelines from the AHA, ACC, and HFSA give SGLT2 inhibitors a class I recommendation for HFrEF regardless of diabetes status, without expressing a preference between empagliflozin and dapagliflozin 11.

Step-by-step switching protocol

Stop the outgoing SGLT2 inhibitor after its last scheduled dose. Start the incoming agent the following day, with or without food. No washout period is needed because the mechanisms are identical and the half-lives are similarly short.

Before switching:

1. Confirm the new agent's approved indication matches the treatment goal (type 2 diabetes, heart failure, or CKD), not every SGLT2 inhibitor is approved for every indication.
2. Check current eGFR. Empagliflozin's glucose-lowering effect diminishes below an eGFR of about 30 mL/min/1.73 m², though its cardiovascular and kidney-protective effects appear to persist at lower eGFR 5. If eGFR has declined meaningfully since the current agent was started, that is a reason to revisit the plan with the prescriber rather than switch reflexively.
3. Review insulin and sulfonylurea doses; a reduction may be reasonable if there is any doubt about hypoglycemia risk during the transition, even though glycemic potency is broadly similar within the class.
4. Discuss genital mycotic infection risk, a class effect reported in a meaningful minority of women and a smaller proportion of men across SGLT2 inhibitors according to product labeling.

After switching:

Recheck serum creatinine and potassium two to four weeks after the switch. An initial eGFR dip of roughly 10 to 15% is an expected hemodynamic effect of starting any SGLT2 inhibitor and does not by itself indicate kidney injury 12; the same pattern can reappear modestly after switching agents. Recheck HbA1c around three months if glycemic control is the treatment target.

Switching from a different drug class to empagliflozin

Moving from a DPP-4 inhibitor (sitagliptin, linagliptin, saxagliptin, alogliptin) to empagliflozin does not require an overlap period, but the two drug classes work differently: DPP-4 inhibitors boost incretin-mediated insulin release, while SGLT2 inhibitors lower glucose independently of insulin. Patients should be told that increased urination in the first days is expected and reflects the drug working as intended, not a problem. The 2024 ADA algorithm favors SGLT2 inhibitors over DPP-4 inhibitors when a patient has established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease 9.

For patients on a GLP-1 receptor agonist, adding an SGLT2 inhibitor rather than switching is common, since the two classes act through complementary mechanisms. A published trial of exenatide once weekly combined with dapagliflozin reportedly produced a larger HbA1c reduction than either drug alone, though exact effect sizes should be checked against the primary publication before being cited precisely.

Patients moving off a sulfonylurea (glimepiride, glipizide) onto empagliflozin should be told that hypoglycemia risk drops, since SGLT2 inhibitors do not stimulate insulin secretion. The sulfonylurea can typically be stopped the same day empagliflozin starts, but glucose should be checked more often in the first week given the change in mechanism.

Switching considerations in heart failure and CKD

In EMPEROR-Reduced, empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 25% versus placebo (HR 0.75, 95% CI 0.65-0.86) in patients with HFrEF 4. In EMPEROR-Preserved, the same dose reduced the same composite endpoint by 21% (HR 0.79, 95% CI 0.69-0.90) in patients with HFpEF 14. Heart failure guidelines recommend an SGLT2 inhibitor regardless of diabetes status and do not prefer one approved agent over another 11, so a heart failure patient stable on dapagliflozin 10 mg who needs to switch for formulary reasons can generally move to empagliflozin 10 mg without a dose change, though the decision should still go through the treating clinician.

EMPA-KIDNEY enrolled 6,609 patients with eGFR 20-45, or 45-90 with a urine albumin-to-creatinine ratio of 200 mg/g or higher, and found a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64-0.82) 5. Switching a CKD patient from canagliflozin 100 mg (the CREDENCE dose) to empagliflozin 10 mg is generally treated as a 1:1 change in SGLT2 inhibition. Volume status should be watched closely in patients also taking a loop diuretic, since the diuretic effect can vary slightly between agents.

Euglycemic DKA risk during a switch

Euglycemic diabetic ketoacidosis is a rare but serious class effect. Population-based cohort studies have estimated the risk as well under 1% per year among SGLT2 inhibitor users, though absolute estimates vary by population and study design and this figure should not be read as a precise universal rate. Switching within the class does not reset or meaningfully change that background risk, but the transition period is still a reasonable time to reinforce warning signs, particularly around illness or surgery.

Current labeling generally recommends stopping an SGLT2 inhibitor for a few days before scheduled surgery, with a somewhat longer hold advised for ertugliflozin given its longer half-life. If a switch is planned around a surgical date, the simplest approach is usually to hold the outgoing agent per surgical guidance, complete the procedure, and start the new SGLT2 inhibitor after oral intake has returned to normal, rather than resuming the old one first.

Patients should be told to report nausea, vomiting, or abdominal pain occurring in the first week on any new SGLT2 inhibitor. A point-of-care blood ketone check is reasonable if euglycemic DKA is suspected; a serum bicarbonate below 18 mmol/L with elevated ketones warrants emergency evaluation regardless of the blood glucose reading.

A framework for the clinician conversation and monitoring after a switch

This is a structure for the conversation with the prescribing clinician, not a substitute for it. It organizes label-level and trial-level information into checkpoints; the actual decision about whether, when, and to what dose to switch belongs to the clinician managing the patient's full history.

Before agreeing to a switch, ask:

• What is this switch for, cost or access, a side effect, or a specific outcome (cardiovascular, heart failure, or kidney) the current agent doesn't have approved evidence for?
• Does the new agent have FDA approval for my specific indication, or only for type 2 diabetes generally?
• Has my kidney function changed since I started the current SGLT2 inhibitor, and does that change the expected benefit?
• Do any of my other medications (insulin, sulfonylurea, diuretic) need a dose adjustment at the same time?

Checkpoint 1, transition day. Last dose of the outgoing agent, first dose of the new agent the next day. Expected: no gap in effect. Not expected: a need to double up doses or wait several days.

Checkpoint 2, first week. Watch for nausea, vomiting, abdominal pain, unusual fatigue, or rapid breathing, which can signal euglycemic DKA even with a normal-looking blood glucose. Watch for genital itching or discharge, and for lightheadedness if also taking a diuretic.

Checkpoint 3, two to four weeks. Recheck serum creatinine, eGFR, and potassium. An eGFR drop of roughly 10 to 15% from baseline is expected and not a reason to stop; a much larger or symptomatic drop is a reason to call the clinician before the next scheduled visit.

Checkpoint 4, around three months. Recheck HbA1c if glycemic control is the goal of the switch. If it has not moved meaningfully, the evidence does not support trying a third SGLT2 inhibitor (see below); the conversation should shift to adding a different class.

Stop and escalate, do not wait for the next visit, if:

• Symptoms suggestive of ketoacidosis appear (nausea, vomiting, abdominal pain, rapid breathing, confusion), even if a home glucose reading looks normal.
• Signs of significant dehydration or a large blood pressure drop appear, especially in someone also on a diuretic or ACE inhibitor/ARB.
• A genital or urinary infection becomes severe, spreads, or does not improve with standard treatment.
• eGFR falls sharply and unexpectedly rather than showing the small, stable dip described above.

What this framework cannot decide for you. Label indications, trial results, and dose-mapping tables describe populations, not the individual patient in front of a clinician. Whether a specific switch is appropriate for someone with, for example, fluctuating kidney function, a recent hospitalization, or several interacting medications is an individualized judgment that depends on information beyond what any general protocol can capture. Use this framework to organize the conversation, not to replace it.

What the evidence does not support

No trial evidence shows that rotating between SGLT2 inhibitors improves outcomes beyond what staying on one agent provides. If a patient is not meeting treatment targets on empagliflozin 25 mg, switching to dapagliflozin 10 mg is unlikely to change the HbA1c trajectory, since the glucose-lowering ceiling is similar across the class.

The better next step in that situation is usually adding a complementary mechanism: a GLP-1 receptor agonist, insulin, or, for heart failure patients, optimized neurohormonal therapy such as sacubitril/valsartan or a mineralocorticoid receptor antagonist. An SGLT2 inhibitor is one part of a treatment plan, not the entire plan.